Document is current
Any future updates will be listed below
-
Authors
Nasrazadani, Azadeh
Marti, Juan Luis Gomez
Lathrop, Kate
Restrepo, Alvaro
Leu, Szu-Yun
Bhat, Gajanan
Brufsky, Adam https://orcid.org/0000-0001-8080-7960
- License Information
-
More Information
Article History
Received: 19 May 2023
Accepted: 22 November 2023
First Online: 23 January 2024
Declarations
:
: AN: Declares that she does not have conflicts of interest. JLGM: declares that he does not have conflicts of interest. ZM: Did not declare any conflicts of interest. KL: Did not declare any conflict of interest. MG: Did not declare any conflict of interest. JP: Did not declare any conflict of interest. KSW: Did not declare any conflicts of interest. JY: Did not declare any conflicts of interest. SS: Did not declare any conflicts of interest. AR: Did not declare any conflicts of interest. GB, SYL: employed at Spectrum Pharmaceuticals. AB: Consultant for Astrazeneca, Pfizer, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, Puma, Myriad, Gilead, Epic Biosciences, Blueprint, Caris, Tempus. Research support from Agendia, Astrazeneca.
: The clinical study protocol and written informed consent form were reviewed and approved by the respective Independent Ethics Committees or IRBs, and consistent with the internal Standard Operating Procedures of Spectrum Pharmaceuticals, Inc. The study was conducted in accordance with Good Clinical Practice. The study was compliant with the World Medical Association Declaration of Helsinki concerning written informed consent and the protection of rights of human subjects.
